What Researchers Did
Researchers investigated combining hyperbaric oxygen therapy with fractionated stereotactic radiotherapy for 25 patients with recurrent high-grade gliomas.
What They Found
The median survival time after treatment was 19 months for patients with anaplastic astrocytoma and 11 months for those with glioblastoma multiforme. Seven patients (28%) underwent subsequent surgery, with 4 of these showing no viable cancer cells and surviving for 50-78 months.
What This Means for Canadian Patients
This approach could offer a potential new treatment option for Canadian patients facing recurrent high-grade gliomas, a condition with limited treatment options. The findings suggest that combining hyperbaric oxygen with radiotherapy might improve survival outcomes for this challenging cancer.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a small study involving only 25 patients, and further larger-scale research is needed to confirm these preliminary findings.